164 related articles for article (PubMed ID: 14601522)
1. The use of virus-like particles for gene transfer.
Petry H; Goldmann C; Ast O; Lüke W
Curr Opin Mol Ther; 2003 Oct; 5(5):524-8. PubMed ID: 14601522
[TBL] [Abstract][Full Text] [Related]
2. Papillomavirus virus-like particles as vehicles for the delivery of epitopes or genes.
Xu YF; Zhang YQ; Xu XM; Song GX
Arch Virol; 2006 Nov; 151(11):2133-48. PubMed ID: 16791442
[TBL] [Abstract][Full Text] [Related]
3. Murine polyomavirus virus-like particles (VLPs) as vectors for gene and immune therapy and vaccines against viral infections and cancer.
Tegerstedt K; Franzén AV; Andreasson K; Joneberg J; Heidari S; Ramqvist T; Dalianis T
Anticancer Res; 2005; 25(4):2601-8. PubMed ID: 16080500
[TBL] [Abstract][Full Text] [Related]
4. Lentivirus-based virus-like particles as a new protein delivery tool.
Muratori C; Bona R; Federico M
Methods Mol Biol; 2010; 614():111-24. PubMed ID: 20225039
[TBL] [Abstract][Full Text] [Related]
5. A top-down approach for construction of hybrid polymer-virus gene delivery vectors.
Ramsey JD; Vu HN; Pack DW
J Control Release; 2010 May; 144(1):39-45. PubMed ID: 20117154
[TBL] [Abstract][Full Text] [Related]
6. Generation and analysis of infectious virus-like particles of uukuniemi virus (bunyaviridae): a useful system for studying bunyaviral packaging and budding.
Overby AK; Popov V; Neve EP; Pettersson RF
J Virol; 2006 Nov; 80(21):10428-35. PubMed ID: 16928751
[TBL] [Abstract][Full Text] [Related]
7. Immunizations with chimeric hepatitis B virus-like particles to induce potential anti-hepatitis C virus neutralizing antibodies.
Vietheer PT; Boo I; Drummer HE; Netter HJ
Antivir Ther; 2007; 12(4):477-87. PubMed ID: 17668556
[TBL] [Abstract][Full Text] [Related]
8. Vesicular stomatitis virus glycoprotein: a transducing coat for SFV-based RNA vectors.
Dorange F; Piver E; Bru T; Collin C; Roingeard P; Pagès JC
J Gene Med; 2004 Sep; 6(9):1014-22. PubMed ID: 15352074
[TBL] [Abstract][Full Text] [Related]
9. Parvovirus B19 VP2-proteins produced in Saccharomyces cerevisiae: comparison with VP2-particles produced by baculovirus-derived vectors.
Lowin T; Raab U; Schroeder J; Franssila R; Modrow S
J Vet Med B Infect Dis Vet Public Health; 2005; 52(7-8):348-52. PubMed ID: 16316399
[TBL] [Abstract][Full Text] [Related]
10. Development of a subunit vaccine for infectious pancreatic necrosis virus using a baculovirus insect/larvae system.
Shivappa RB; McAllister PE; Edwards GH; Santi N; Evensen O; Vakharia VN
Dev Biol (Basel); 2005; 121():165-74. PubMed ID: 15962479
[TBL] [Abstract][Full Text] [Related]
11. Development of a microRNA delivery system based on bacteriophage MS2 virus-like particles.
Pan Y; Zhang Y; Jia T; Zhang K; Li J; Wang L
FEBS J; 2012 Apr; 279(7):1198-208. PubMed ID: 22309233
[TBL] [Abstract][Full Text] [Related]
12. Influenza virus-like particles elicit broader immune responses than whole virion inactivated influenza virus or recombinant hemagglutinin.
Bright RA; Carter DM; Daniluk S; Toapanta FR; Ahmad A; Gavrilov V; Massare M; Pushko P; Mytle N; Rowe T; Smith G; Ross TM
Vaccine; 2007 May; 25(19):3871-8. PubMed ID: 17337102
[TBL] [Abstract][Full Text] [Related]
13. Virus-like particles exhibit potential as a pan-filovirus vaccine for both Ebola and Marburg viral infections.
Swenson DL; Warfield KL; Negley DL; Schmaljohn A; Aman MJ; Bavari S
Vaccine; 2005 Apr; 23(23):3033-42. PubMed ID: 15811650
[TBL] [Abstract][Full Text] [Related]
14. Characterization of a DNA vaccine expressing a human immunodeficiency virus-like particle.
Young KR; Smith JM; Ross TM
Virology; 2004 Oct; 327(2):262-72. PubMed ID: 15351214
[TBL] [Abstract][Full Text] [Related]
15. Toward development of artificial viruses for gene therapy: a comparative evaluation of viral and non-viral transfection.
Douglas KL
Biotechnol Prog; 2008; 24(4):871-83. PubMed ID: 18335953
[TBL] [Abstract][Full Text] [Related]
16. A novel system for efficient gene transfer into primary human hepatocytes via cell-permeable hepatitis B virus-like particle.
Brandenburg B; Stockl L; Gutzeit C; Roos M; Lupberger J; Schwartlander R; Gelderblom H; Sauer IM; Hofschneider PH; Hildt E
Hepatology; 2005 Dec; 42(6):1300-9. PubMed ID: 16317706
[TBL] [Abstract][Full Text] [Related]
17. Removal of empty capsids from type 1 adeno-associated virus vector stocks by anion-exchange chromatography potentiates transgene expression.
Urabe M; Xin KQ; Obara Y; Nakakura T; Mizukami H; Kume A; Okuda K; Ozawa K
Mol Ther; 2006 Apr; 13(4):823-8. PubMed ID: 16473554
[TBL] [Abstract][Full Text] [Related]
18. Recombinant VP60 in the form of virion-like particles as a potential vaccine against rabbit hemorrhagic disease virus.
Gromadzka B; Szewczyk B; Konopa G; Fitzner A; Kesy A
Acta Biochim Pol; 2006; 53(2):371-6. PubMed ID: 16733562
[TBL] [Abstract][Full Text] [Related]
19. Enhanced cellular uptake of virus-like particles through immobilization on a sialic acid-displaying solid surface.
Ohtake N; Niikura K; Suzuki T; Nagakawa K; Sawa H; Ijiro K
Bioconjug Chem; 2008 Feb; 19(2):507-15. PubMed ID: 18179162
[TBL] [Abstract][Full Text] [Related]
20. Cell death induced by the herpes simplex virus-1 thymidine kinase delivered by human immunodeficiency virus-1-based virus-like particles.
Peretti S; Schiavoni I; Pugliese K; Federico M
Mol Ther; 2005 Dec; 12(6):1185-96. PubMed ID: 16095973
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
